A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants With Schizophrenia
Latest Information Update: 25 Jul 2025
At a glance
- Drugs Olanzapine (Primary) ; Olanzapine
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Teva Branded Pharmaceutical Products R&D
Most Recent Events
- 15 Jul 2025 Planned End Date changed from 14 Jun 2025 to 12 Sep 2025.
- 15 Jul 2025 Planned primary completion date changed from 14 Jun 2025 to 15 Aug 2025.
- 22 May 2025 Status changed from recruiting to active, no longer recruiting.